Singapore markets closed

Ultragenyx Pharmaceutical Inc. (0LIF.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
42.67-1.31 (-2.98%)
As of 04:42PM BST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.66
52-week change 321.78%
S&P500 52-week change 324.49%
52-week high 354.48
52-week low 30.00
50-day moving average 347.46
200-day moving average 343.02

Share statistics

Avg vol (3-month) 3302
Avg vol (10-day) 3203
Shares outstanding 550.58M
Implied shares outstanding 6N/A
Float 873.41M
% held by insiders 14.02%
% held by institutions 1100.60%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -138.58%
Operating margin (ttm)-151.93%

Management effectiveness

Return on assets (ttm)-26.97%
Return on equity (ttm)-340.05%

Income statement

Revenue (ttm)442.59M
Revenue per share (ttm)5.75
Quarterly revenue growth (yoy)8.30%
Gross profit (ttm)N/A
EBITDA -550.84M
Net income avi to common (ttm)-613.35M
Diluted EPS (ttm)-6.87
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)412.08M
Total cash per share (mrq)4.96
Total debt (mrq)932.17M
Total debt/equity (mrq)664.59%
Current ratio (mrq)2.43
Book value per share (mrq)1.69

Cash flow statement

Operating cash flow (ttm)-508.67M
Levered free cash flow (ttm)-329.48M